RT Journal Article
SR Electronic
T1 Combined cerebrospinal fluid metabolomic and cytokine profiling in tuberculosis meningitis reveals robust and prolonged changes in immunometabolic networks
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.26.23291676
DO 10.1101/2023.06.26.23291676
A1 Tomalka, Jeff
A1 Sharma, Ashish
A1 Smith, Alison G.C.
A1 Avaliani, Teona
A1 Gujabidze, Mariam
A1 Bakuradze, Tinatin
A1 Sabanadze, Shorena
A1 Jones, Dean P.
A1 Avaliani, Zaza
A1 Kipiani, Maia
A1 Kempker, Russell R.
A1 Collins, Jeffrey M.
YR 2023
UL http://medrxiv.org/content/early/2023/06/29/2023.06.26.23291676.abstract
AB Much of the high mortality in tuberculosis meningitis (TBM) is attributable to excessive inflammation, making it imperative to identify targets for host-directed therapies that reduce pathologic inflammation and mortality. In this study, we investigate how cytokines and metabolites in the cerebral spinal fluid (CSF) associate with TBM at diagnosis and during TBM treatment. At diagnosis, TBM patients demonstrate significant increases versus controls of cytokines and chemokines that promote inflammation and cell migration including IL-17A, IL-2, TNFα, IFNγ, and IL-1β. Inflammatory immune signaling was strongly correlated with immunomodulatory metabolites including kynurenine, lactic acid, carnitine, tryptophan, and itaconate. Inflammatory immunometabolic networks were only partially reversed with two months of effective TBM treatment and remained significantly different versus control CSF. Together, these data highlight a critical role for host metabolism in regulating the inflammatory response to TBM and indicate the timeline for restoration of immune homeostasis in the CSF is prolonged.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases [R03AI139871, K23AI103044, K23AI144040, P30AI168386, P30AI050409]; NIH Fogarty International Center [D43TW007124]; and NIH National Center for Advancing Translational Science [UL1TR002378], Bethesda, MD, USA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review boards of Emory University and the National Center for Tuberculosis and Lung Disease gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.